{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:45:09Z","timestamp":1792107909758,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00467-026-07445-w","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:15:54Z","timestamp":1783505754000},"page":"4561-4572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of the comparative efficacy and safety of obinutuzumab and other follow-up strategies after rituximab failure in refractory nephrotic syndrome"],"prefix":"10.1007","volume":"41","author":[{"given":"Haoyu","family":"Zha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"7445_CR1","doi-asserted-by":"crossref","unstructured":"Veltkamp F, Rensma LR, Bouts AHM; LEARNS consortium (2021) Incidence and relapse of idiopathic nephrotic syndrome: meta-analysis. Pediatrics 148:e2020029249","DOI":"10.1542\/peds.2020-029249"},{"key":"7445_CR2","doi-asserted-by":"publisher","first-page":"e13157","DOI":"10.1097\/MD.0000000000013157","volume":"97","author":"YH Ahn","year":"2018","unstructured":"Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW et al (2018) Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine (Baltimore) 97:e13157","journal-title":"Medicine (Baltimore)"},{"key":"7445_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K et al (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273\u20131281","journal-title":"Lancet"},{"key":"7445_CR4","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00467-020-04540-4","volume":"35","author":"P Ravani","year":"2020","unstructured":"Ravani P, Lugani F, Pisani I, Bodria M, Piaggio G, Bartolomeo D et al (2020) Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomised controlled study. Pediatr Nephrol 35:1437\u20131444","journal-title":"Pediatr Nephrol"},{"key":"7445_CR5","doi-asserted-by":"publisher","first-page":"728010","DOI":"10.3389\/fped.2021.728010","volume":"9","author":"S Liu","year":"2021","unstructured":"Liu S, Gui C, Lu Z, Li H, Fu Z, Deng Y (2021) The efficacy and safety of rituximab for childhood steroid-dependent nephrotic syndrome: a systematic review and meta-analysis. Front Pediatr 9:728010. https:\/\/doi.org\/10.3389\/fped.2021.728010","journal-title":"Front Pediatr"},{"key":"7445_CR6","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ekir.2024.02.1395","volume":"9","author":"J Liu","year":"2024","unstructured":"Liu J, Deng F, Wang X, Sun S, Zhang R, Zhang A et al (2024) Early rituximab as an add-on therapy in children with the initial episode of nephrotic syndrome. Kidney Int Rep 9:1220\u20131227","journal-title":"Kidney Int Rep"},{"key":"7445_CR7","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1007\/s00467-022-05475-8","volume":"37","author":"G Mathew","year":"2022","unstructured":"Mathew G, Sinha A, Ahmed A, Grewal N, Khandelwal P, Hari P et al (2022) Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial. Pediatr Nephrol 37:3117\u20133126","journal-title":"Pediatr Nephrol"},{"key":"7445_CR8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.medcli.2020.07.039","volume":"157","author":"D Chang","year":"2021","unstructured":"Chang D, Gong M, Liu C, Zhang Q, Hu Z, Li Z (2021) Efficacy and safety of rituximab for childhood refractory nephrotic syndrome: a meta-analysis of randomized controlled trials. Med Clin (Barc) 157:418\u2013426. https:\/\/doi.org\/10.1016\/j.medcli.2020.07.039","journal-title":"Med Clin (Barc)"},{"key":"7445_CR9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K et al (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273\u20131281. https:\/\/doi.org\/10.1016\/S0140-6736(14)60541-9","journal-title":"Lancet"},{"key":"7445_CR10","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, Br\u00fcnker P, Moser S, P\u00fcntener U, Schmidt C, Herter S et al (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393\u20134402","journal-title":"Blood"},{"key":"7445_CR11","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1182\/blood.2024024476","volume":"146","author":"JP Sharman","year":"2025","unstructured":"Sharman JP, Egyed M, Jurczak W et al (2025) Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood 146:1276\u20131285. https:\/\/doi.org\/10.1182\/blood.2024024476","journal-title":"Blood"},{"key":"7445_CR12","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","volume":"22","author":"MS Davids","year":"2021","unstructured":"Davids MS, Lampson BL, Tyekucheva S, Wang Z, Lowney JC, Pazienza S et al (2021) Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol 22:1391\u20131402","journal-title":"Lancet Oncol"},{"key":"7445_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A et al (2022) B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis. A randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81:100\u2013107","journal-title":"Ann Rheum Dis"},{"key":"7445_CR14","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie RA, Rovin BH, Garg JP et al (2025) Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med 392:1471\u20131483. https:\/\/doi.org\/10.1056\/NEJMoa2410965","journal-title":"N Engl J Med"},{"key":"7445_CR15","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2215\/CJN.0000000000000288","volume":"18","author":"C Dossier","year":"2023","unstructured":"Dossier C, Bonneric S, Baudouin V, Cambier A, Hogan J, Boyer O et al (2023) Obinutuzumab in frequently relapsing and steroid-dependent nephrotic syndrome in children. Clin J Am Soc Nephrol 18:1555\u20131562","journal-title":"Clin J Am Soc Nephrol"},{"key":"7445_CR16","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ki.2013.211","volume":"84","author":"P Ravani","year":"2013","unstructured":"Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F et al (2013) Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 84:1025\u20131033","journal-title":"Kidney Int"},{"key":"7445_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1310032","volume":"15","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Chen J, Zhang Y, Wang X, Wang J (2024) Immunosuppressive agents for frequently relapsing\/steroid-dependent nephrotic syndrome in children: a systematic review and network meta-analysis. Front Immunol 15:1310032","journal-title":"Front Immunol"},{"key":"7445_CR18","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1681\/ASN.2021111472","volume":"33","author":"EY Chan","year":"2022","unstructured":"Chan EY, Yu ELM, Angeletti A et al (2022) Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study. J Am Soc Nephrol 33:1193\u20131207. https:\/\/doi.org\/10.1681\/ASN.2021111472","journal-title":"J Am Soc Nephrol"},{"key":"7445_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/17843286.2016.1208955","volume":"72","author":"I Van Horebeek","year":"2017","unstructured":"Van Horebeek I, Knops N, Van Dyck M, Levtchenko E, Mekahli D (2017) Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary centre and review of the literature. Acta Clin Belg 72:147\u2013155","journal-title":"Acta Clin Belg"},{"key":"7445_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100791","volume":"6","author":"T Salehi","year":"2024","unstructured":"Salehi T, Krishnan A, Al Jurdi A, So P, Lerma E, Wiegley N (2024) Rituximab resistance in glomerular diseases: a GlomCon mini review. Kidney Med 6:100791","journal-title":"Kidney Med"},{"key":"7445_CR21","doi-asserted-by":"crossref","unstructured":"Shah K, Klein C, Cambridge G, Smith J, Patel R, Thompson L et al (2023) P167 Overcoming rituximab resistance in autoimmune disease: back to basics. Rheumatology 62(Suppl 2):kead104.208","DOI":"10.1093\/rheumatology\/kead104.208"},{"key":"7445_CR22","doi-asserted-by":"publisher","first-page":"973609","DOI":"10.1155\/2014\/973609","volume":"2014","author":"P Pateinakis","year":"2014","unstructured":"Pateinakis P, Pyrpasopoulou A (2014) CD20+ B cell depletion in systemic autoimmune diseases: common mechanism of inhibition or disease-specific effect on humoral immunity? Biomed Res Int 2014:973609","journal-title":"Biomed Res Int"},{"key":"7445_CR23","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova G, Mraz M (2020) The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica 105:1494\u20131506","journal-title":"Haematologica"},{"key":"7445_CR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1053\/j.seminoncol.2014.08.006","volume":"41","author":"B Bonavida","year":"2014","unstructured":"Bonavida B (2014) Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. Semin Oncol 41:667\u2013677","journal-title":"Semin Oncol"},{"key":"7445_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00467-021-05069-w","volume":"37","author":"Q Bertrand","year":"2022","unstructured":"Bertrand Q, Mignot S, Kwon T, Couderc A, Maisin A, Cambier A et al (2022) Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome. Pediatr Nephrol 37:357\u2013365","journal-title":"Pediatr Nephrol"},{"key":"7445_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.15232","volume":"182","author":"CL Freeman","year":"2018","unstructured":"Freeman CL, Sehn LH (2018) A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol 182:29\u201345","journal-title":"Br J Haematol"},{"key":"7445_CR27","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.ekir.2024.05.004","volume":"9","author":"X Su","year":"2024","unstructured":"Su X, Wu B, Tie X, Guo X, Feng R, Qiao X et al (2024) Obinutuzumab as initial or second-line therapy in patients with primary membranous nephropathy. Kidney Int Rep 9:2386\u20132398","journal-title":"Kidney Int Rep"},{"key":"7445_CR28","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/ndt\/gfae230","volume":"40","author":"M Xu","year":"2025","unstructured":"Xu M, Wang Y, Wu M, Chen R, Zhao W, Li M et al (2025) Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy. Nephrol Dial Transplant 40:978\u2013986","journal-title":"Nephrol Dial Transplant"},{"key":"7445_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fped.2019.00178","volume":"7","author":"M Kallash","year":"2019","unstructured":"Kallash M, Smoyer WE, Mahan JD (2019) Rituximab use in the management of childhood nephrotic syndrome. Front Pediatr 7:178","journal-title":"Front Pediatr"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07445-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07445-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07445-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:54:08Z","timestamp":1792104848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07445-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["7445"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07445-w","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study conformed to the Declaration of Helsinki and was approved by the Ethics Committee of Capital Center for Children's Health, Capital Medical University (No. SHERLLM2025030). The requirement for written informed consent was waived by the committee of Capital Center for Children's Health, Capital Medical University due to the retrospective nature of the study and the use of anonymized data.","order":1,"name":"Ethics","label":"Statement of ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}